Full Title: rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
Status: Active, Recruiting
Age Range: 4 - 50 years
Locations:
- Cardiff & Vale Lhb, Cardiff
- Beaston West of Scotland Cancer Centre, Glasgow
- Nottingham University Hospital's NHS Trust - City Campus, Nottingham
- Churchill Hospital, Oxford
- Weston Park Hospital, Sheffield
- Clatterbridge Cancer Centre, Wirral
- University College Hospital, London
- Queen Elizabeth Hospital, Birmingham
- Leicester Royal Infirmary, Leicester
- Sheffield Children's Hospital, Sheffield
- The Royal Marsden Hospital (Surrey), Sutton
- The Royal Marsden Hospital (London), London
- Southampton General Hospital, Southampton
- Addenbrooke's Hospital, Cambridge
- Birmingham Children's Hospital, Birmingham
- Clarendon Wing, Leeds General Infirmary, Leeds
- Nottingham University Hospitals NHS Trust - Queen's Medical Centre Campus, Nottingham
- John Radcliffe Hospital, Oxford
- University Hospital, Leeds
- Alder Hey Children's NHS Foundation Trust, Liverpool
- Bristol Royal Hospital For Children, Bristol
- Royal Hospital for Sick Children, Glasgow
- Royal Manchester Children's Hospital, Manchester
- University Hospitals Bristol and Weston NHS Foundation Trust, Bristol
- Royal Aberdeen Children's Hospital, Aberdeen
- Royal Hospital for Sick Children, Edinburgh
- The Royal Belfast Hospital for Sick Children, Belfast
Trial Lead: Dr Martin McCabe
Ewing sarcoma is treated with a combination of surgery, chemotherapy or radiotherapy. However, if it does not respond to these treatments, or comes back afterwards, there isn’t a standard treatment for patients to receive.
rEECur is an international trial, which aims to compare different chemotherapy combinations or ‘regimens’ to find out which is most effective and/or has fewest side effects. Four chemotherapy regimens formed the four original trial ‘arms’ (the different options which participants could be assigned to), as listed below.
Following early analyses, three out of the four original arms have now closed to recruitment. So far, high dose Ifosfamide has proven to be the most effective option. A fifth chemotherapy arm (CE) has now been added to the study.
TOPOTECAN AND CYCLOPHOSPHAMIDE (TC) - update: this arm has been dropped.
IRINOTECAN AND TEMOZOLOMIDE (IT) - update: this arm has been dropped.
GEMCITABINE AND DOCETAXEL (GD) - update: this arm has been dropped.
HIGH DOSE IFOSFAMIDE (IFOS) – open
CARBOPLATIN + ETOPOSIDE (CE) – fifth arm, open, added at a later stage
The trial is being run as it is not known which is the best treatment for this group of patients. The trial is randomised, meaning patients will be randomly assigned to a treatment arm by a computer. This is done so that neither the patient nor their doctor will be able to influence which treatment arm the patient is given and means that the results of the trial are not biased in any way.
BCRT have recently awarded additional top-up funding for a targeted drug called Lenvatinib to be added to the trial, given in combination with high dose Ifosfamide (Lenvatinib + IFOS).
Lenvatinib is a type of drug known as a multi-tyrosine kinase inhibitor. It has demonstrated promising results when given alone (as a ‘single agent’) to patients whose Ewing sarcoma has returned. With this additional funding, the rEECur team will now test whether Levatinib given with chemotherapy is more effective than chemotherapy alone.
Approvals for this additional research have now been granted and recruitment to this arm will begin shortly. You can read more
about this further research here.
The study is supported by the European Commission’s FP7 health programme, Cancer Research UK and The University of Birmingham. More information about the trial can be found on their website
If you would like any more information on clinical trials in general, please contact us at The Bone Cancer Research Trust.
Donate now (This link opens in a new window) More about Ewing sarcoma